Pharmacokinetics of dalbavancin in plasma and skin blister fluid

Journal of Antimicrobial Chemotherapy

Volumn 60, Issue 3, 2007, Pages 681-684

  Nicolau, David P ^a   Sun, Heather K ^a   Seltzer, Elyse ^b   Buckwalter, Mary ^b   Dowell, James A ^b  

^a HARTFORD HOSPITAL   (United States)

^b Vicuron Pharmaceuticals   (United States)

Author keywords

CSSSIs; Infections; Lipoglycopeptides

Indexed keywords

CANTHARIDIN; DALBAVANCIN;

ADULT; ANTIBIOTIC SENSITIVITY; AREA UNDER THE CURVE; ARTICLE; BACKACHE; BETA HEMOLYTIC STREPTOCOCCUS; BLISTER; BLOOD SAMPLING; CLINICAL TRIAL; CONSTIPATION; COUGHING; DRUG BLOOD LEVEL; DRUG FATALITY; DRUG INDUCED HEADACHE; DRUG PENETRATION; EAR INFECTION; FEMALE; HUMAN; HUMAN EXPERIMENT; INJECTION SITE ERYTHEMA; INJECTION SITE PAIN; KERATOCONJUNCTIVITIS SICCA; LIQUID CHROMATOGRAPHY; LOOSE FECES; MALE; MAXIMUM PLASMA CONCENTRATION; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; NAUSEA; NORMAL HUMAN; OCULAR PRURITUS; SIDE EFFECT; SINGLE DRUG DOSE; SINUS CONGESTION; SNEEZING; TANDEM MASS SPECTROMETRY; UNSPECIFIED SIDE EFFECT; VOMITING;

ADULT; ANTI-BACTERIAL AGENTS; AREA UNDER CURVE; BIOTRANSFORMATION; BLISTER; CANTHARIDIN; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; IRRITANTS; MALE; MIDDLE AGED; PLASMA; SKIN; TANDEM MASS SPECTROMETRY; TEICOPLANIN;

EID: 34548128399     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkm263     Document Type: Article

References (16)

1. Anderson JS, Matsuhashi M, Haskin MA et al. Lipid-phosphoacetylmuramyl-pentapeptide and lipid-phosphodisaccharide-pentapeptide: Presumed membrane transport intermediates in cell wall synthesis. Proc Natl Acad Sci USA 1965; 53: 881-9.
2. Streit JM, Sader HS, Fritsche TR et al. Dalbavancin activity against selected populations of antimicrobial-resistant Gram-positive pathogens. Diagn Microbiol Infect Dis 2005; 53: 307-10.
3. Candiani G, Abbondi M, Borgonovi M et al. in-vitro and in-vivo antibacterial activity of BI 397 a new semi-synthetic glycopeptide antibiotic. J Antimicrob Chemother 1999; 44: 179-92.
4. Seltzer E, Dorr MB, Goldstein BP et al. Once-weekly dalbavancin versus standard-of-care antimicrobial regimens for treatment of skin and soft-tissue infections. Clin Infect Dis 2003; 37: 1298-303.
5. Streit JM, Fritsche TR, Sader HS et al. Worldwide assessment of dalbavancin activity spectrum against over 6000 clinical isolates. Diagn Microbiol Infect Dis 2004; 48: 137-43.
6. Dowell JA, Gottlieb AB, VanSaders C et al. The pharmaco-kinetics and renal excretion of dalbavancin in healthy subjects. In: Abstracts of the Forty-second interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, CA, 2002. Abstract A-1386, p. 18. American Society for Microbiology, Washington, DC, USA.
7. Stogniew M, Pu F, Dowell J. Attributes of dalbavancin: Well distributed and completely eliminated. Clin Microbiol Infect 2003; 9 Suppl 1: 291-2.
8. Dorr MB, Jabes D, Cavaleri M et al. Human pharmacokinetics and rationale for once-weekly dosing of dalbavancin, a semi-synthetic glycopeptide. J Antimicrob Chemother 2005; 55 Suppl 2: ii25-30.
9. Cavaleri M, Riva S, Valagussa. A et al Pharmacokinetics and excretion of dalbavancin in the rat. J Antimicrob Chemother 2005; 55 Suppl 2: Ii31-5.
10. Federal Food Drug Administration. Uncomplicated and Complicated Skin and Skin Structure Infections - Developing Antimicrobial Drugs for Treatment. Guidance for Industry. Draft Guidance. July, 1998. http://www.fda.gov/cder/guidance/index.htm (12 December 2005, date last accessed).
11. Maglio D, Nightingale CH, Nicolau DP. Production and resolution of cantharidin-induced inflammatory blisters. Int J Antimicrob Agents 2003; 22: 77-80.
12. Leighton A, Gottlieb AB, Dorr MB et al. Tolerability, pharmacokinetics and serum bactericidal activity of intravenous dalbavancin in healthy volunteers. Antimicrob Agents Chemother 2004; 48: 940-5.
13. Andes DR, Craig WA. In vivo pharmacodynamic characterization of dalbavancin (DAL) in the murine thigh infection model. In: Abstracts of the Forty-fourth Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, DC, 2004. Abstract A-1872, p. 39. American Society for Microbiology, Washington, DC, USA.
14. Sun HK, Duchin K, Nightingale CH et al. Tissue penetration of telavancin after intravenous administration in healthy subjects. Antimicrob Agents Chemother 2006; 50: 788-90.
15. Fetterly GJ, Ong CM, Bhavnani SM et al. Pharmacokinetics of oritavancin in plasma skin blister fluid following administration of a 200-milligram dose for 3 days or a single 800-milligram dose. Antimicrob Agents Chemother 2005; 49: 148-52.
16. Jauregui LE, Babazadeh S, Seltzer E et al. Randomized, double-blind comparison of once-weekly dalbavancin versus twice-daily linezolid therapy for the treatment of complicated skin and skin structure infections. Clin Infect Dis 2005; 41: 1407-15.